Leslie Thomas, MD
Nephrology · Phoenix, AZNPI 1053386169
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,408 of the $21,680 with a category attached, or 89.5%. Novartis accounts for 75.5% of it on its own, with 5 other manufacturers making up the rest. 2024 is the largest year on record at $7,611, 2.1 times the $3,638 reported in 2020. Among nephrology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 18 payments — averaging $1204.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$16K
- Calliditas Therapeutics US Inc.$4K
- Daxor Corporation$1K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$217
- Ultragenyx Pharmaceutical Inc.$30
- Outset Medical Inc$27
Across 22 payments — averaging $137,660 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.4M
- Genentech, Inc.$415K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$128K
- AstraZeneca$49K
What the payments were for
- Consulting fees$19,40890%
- Travel & lodging$1,5077%
- Food & beverage$7363%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 10 | $16,379 |
| Calliditas Therapeutics US Inc. | 4 | $3,827 |
| Daxor Corporation | 1 | $1,200 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $217 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
| Outset Medical Inc | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,680 in reported general payments places this provider in the 95th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mycophenolate Mofetil | 22 | $5,334 |
| ProsolParenteral Amino Acid 20% No.1 | 12 | $2,875 |
| Sevelamer Carbonate | 15 | $1,641 |
| Torsemide | 47 | $758 |
| Amlodipine Besylate | 27 | $333 |
| Prednisone | 18 | $227 |
| Carvedilol | 15 | $201 |
| Losartan Potassium | 18 | $167 |
| Allopurinol | 17 | $155 |
| Lisinopril | 20 | $146 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Phoenix
- Samer Bani HaniPhoenix$54K
- Alexander NimriPhoenix$21K
- Edgardo LaurelPhoenix$15K
- Sharareh SaadatPhoenix$15K
- Amar BistaPhoenix$12K
- Maher MousaPhoenix$9K
- Paul SacksPhoenix$8K
- William WeissPhoenix$8K
- Esmat MustafaPhoenix$7K
- Hui ZhaoPhoenix$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.